137 related articles for article (PubMed ID: 35635145)
1. Design, synthesis and biological evaluation of novel triazoloquinazolinone and imidazoquinazolinone derivatives as allosteric inhibitors of SHP2 phosphatase.
Ye W; Liu Y; Ren Q; Liao T; Chen Y; Chen D; Wang S; Yao L; Jia Y; Zhao C; Zhou Z
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1495-1513. PubMed ID: 35635145
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of novel triazoloquinazolinone derivatives as SHP2 protein inhibitors.
Luo R; Wang Z; Luo D; Qin Y; Zhao C; Yang D; Lu T; Zhou Z; Huang Z
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2170-2182. PubMed ID: 34749564
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of small peptide compounds, molecular docking, and inhibitory activity evaluation against phosphatases PTP1B and SHP2.
Kostrzewa T; Sahu KK; Gorska-Ponikowska M; Tuszynski JA; Kuban-Jankowska A
Drug Des Devel Ther; 2018; 12():4139-4147. PubMed ID: 30584278
[TBL] [Abstract][Full Text] [Related]
4. Benzo[c][1,2,5]thiadiazole derivatives: A new class of potent Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.
Wang WL; Chen XY; Gao Y; Gao LX; Sheng L; Zhu J; Xu L; Ding ZZ; Zhang C; Li JY; Li J; Zhou YB
Bioorg Med Chem Lett; 2017 Dec; 27(23):5154-5157. PubMed ID: 29100798
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of pyridine derivatives as selective SHP2 inhibitors.
Liu WS; Yang B; Wang RR; Li WY; Ma YC; Zhou L; Du S; Ma Y; Wang RL
Bioorg Chem; 2020 Jul; 100():103875. PubMed ID: 32380342
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of 2,5-diaryl-1,3,4-oxadiazole derivatives as novel Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) inhibitors.
Meng XD; Gao LX; Wang ZJ; Feng B; Zhang C; Satheeshkumar R; Li J; Zhu YL; Zhou YB; Wang WL
Bioorg Chem; 2021 Nov; 116():105384. PubMed ID: 34601294
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of heterocyclic bis-aryl amides as novel Src homology 2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors.
Satheeshkumar R; Zhu R; Feng B; Huang C; Gao Y; Gao LX; Shen C; Hou TJ; Xu L; Li J; Zhu YL; Zhou YB; Wang WL
Bioorg Med Chem Lett; 2020 Jun; 30(11):127170. PubMed ID: 32273218
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, activity and molecular dynamics studies of 1,3,4-thiadiazole derivatives as selective allosteric inhibitors of SHP2 for the treatment of cancer.
Liu WS; Zhao JF; Guo XJ; Lu SZ; Li W; Li WZ
Eur J Med Chem; 2023 Oct; 258():115585. PubMed ID: 37390510
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.
Grosskopf S; Eckert C; Arkona C; Radetzki S; Böhm K; Heinemann U; Wolber G; von Kries JP; Birchmeier W; Rademann J
ChemMedChem; 2015 May; 10(5):815-26. PubMed ID: 25877780
[TBL] [Abstract][Full Text] [Related]
10. Emerging chemical scaffolds with potential SHP2 phosphatase inhibitory capabilities - A comprehensive review.
Tripathi RKP; Ayyannan SR
Chem Biol Drug Des; 2021 Mar; 97(3):721-773. PubMed ID: 33191603
[TBL] [Abstract][Full Text] [Related]
11. Novel PROTACs for degradation of SHP2 protein.
Zheng M; Liu Y; Wu C; Yang K; Wang Q; Zhou Y; Chen L; Li H
Bioorg Chem; 2021 May; 110():104788. PubMed ID: 33706076
[TBL] [Abstract][Full Text] [Related]
12. Scaffold-based selective SHP2 inhibitors design using core hopping, molecular docking, biological evaluation and molecular simulation.
Li WY; Ma Y; Li HX; Lu XH; Du S; Ma YC; Zhou L; Wang RL
Bioorg Chem; 2020 Dec; 105():104391. PubMed ID: 33113413
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of open-chain analogs of cyclic peptides as inhibitors of cellular Shp2 activity.
Zhen XL; Yin WH; Tian X; Ma ZJ; Fan SM; Han JR; Liu S
Bioorg Med Chem; 2015 May; 23(10):2562-7. PubMed ID: 25865131
[TBL] [Abstract][Full Text] [Related]
14. Structure based design of selective SHP2 inhibitors by De novo design, synthesis and biological evaluation.
Liu WS; Jin WY; Zhou L; Lu XH; Li WY; Ma Y; Wang RL
J Comput Aided Mol Des; 2019 Aug; 33(8):759-774. PubMed ID: 31300938
[TBL] [Abstract][Full Text] [Related]
15. Scaffold-based novel SHP2 allosteric inhibitors design using Receptor-Ligand pharmacophore model, virtual screening and molecular dynamics.
Jin WY; Ma Y; Li WY; Li HL; Wang RL
Comput Biol Chem; 2018 Apr; 73():179-188. PubMed ID: 29494926
[TBL] [Abstract][Full Text] [Related]
16. Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment.
Kerr DL; Haderk F; Bivona TG
Curr Opin Chem Biol; 2021 Jun; 62():1-12. PubMed ID: 33418513
[TBL] [Abstract][Full Text] [Related]
17. Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors.
Bagdanoff JT; Chen Z; Acker M; Chen YN; Chan H; Dore M; Firestone B; Fodor M; Fortanet J; Hentemann M; Kato M; Koenig R; LaBonte LR; Liu S; Mohseni M; Ntaganda R; Sarver P; Smith T; Sendzik M; Stams T; Spence S; Towler C; Wang H; Wang P; Williams SL; LaMarche MJ
J Med Chem; 2019 Feb; 62(4):1781-1792. PubMed ID: 30688462
[TBL] [Abstract][Full Text] [Related]
18. Allosteric modulation of SHP2: Quest from known to unknown.
Wang N; Zhu S; Lv D; Wang Y; Khawar MB; Sun H
Drug Dev Res; 2023 Nov; 84(7):1395-1410. PubMed ID: 37583266
[TBL] [Abstract][Full Text] [Related]
19. From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement.
Mostinski Y; Heynen GJJE; López-Alberca MP; Paul J; Miksche S; Radetzki S; Schaller D; Shanina E; Seyffarth C; Kolomeets Y; Ziebart N; de Schryver J; Oestreich S; Neuenschwander M; Roske Y; Heinemann U; Rademacher C; Volkamer A; von Kries JP; Birchmeier W; Nazaré M
J Med Chem; 2020 Dec; 63(23):14780-14804. PubMed ID: 33210922
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors.
Tang K; Zhao M; Wu YH; Wu Q; Wang S; Dong Y; Yu B; Song Y; Liu HM
Eur J Med Chem; 2022 Feb; 230():114106. PubMed ID: 35063735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
